1. AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection
- Author
-
Jones, Norman G., DeCamp, Allan, Gilbert, Peter, Peterson, Michael L., Gurwith, Marc, and Cao, Huyen
- Subjects
- *
AIDS vaccines , *HIV infection transmission , *DRUG efficacy , *T cells , *AIDS prevention , *IMMUNE response , *BIOMARKERS , *PUBLIC health - Abstract
Abstract: Correlates of immune protection from HIV vaccines remain undefined. The first HIV vaccine efficacy trial in the US and Europe VAX004, was designed to assess whether rgp120 envelope subunits (AIDSVAX B/B, VaxGen) can induce partial or complete protection from HIV-1 infection. No effectiveness in the reduction of either the acquisition of infection or levels of plasma viremia after HIV infection was noted. We found evidence of vaccine-specific CD8+ T cells in volunteers who received the vaccine, regardless of behavioral risk. Surprisingly, the CD8-response is significantly higher in participants who would go on to contract HIV infection. These results suggest that AIDSVAX immunization may boost preexisting immune responses—due to pre-infection exposure, and a vaccine-induced immune profile may serve as a biological marker for HIV susceptibility. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF